Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
|Videos|June 24, 2022
Dr. Miller: “No limits” to what HoLEP can offer appropriate patients with BPH
Author(s)Urology Times staff
“We're doing probably one of the highest volume of HoLEP cases…in the United States,” says Nicole L. Miller, MD, FACS.
Advertisement
In this video, Nicole L. Miller, MD, FACS, discusses what sets her HoLEP practice for treating patients with benign prostatic hyperplasia from other centers. Miller is a professor of urology and fellowship director, Endourology and Laparoscopic Surgery, at Vanderbilt University Medical Center in Nashville, Tennessee.
Advertisement
Related to this article
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
3
Infertility care: Examining geographic gaps in access
4
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
5